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Acute myeloid leukemia (AML) is a heterogeneous disease caused by a variety of mutations 27 
in transcription factors, epigenetic regulators and signaling molecules. To determine how 28 
different mutant regulators establish AML subtype-specific transcriptional networks we 29 
performed a comprehensive global analysis of cis-regulatory element activity and interaction, 30 
transcription factor occupancy and gene expression patterns in purified leukemic blast cells. 31 
Here, we focussed on specific sub-groups of patients carrying mutations in genes encoding 32 
transcription factors (RUNX1, CEBPA) and signaling molecules (FTL3-ITD, RAS, NPM1). 33 
Integrated analyses of these data demonstrates that each mutant regulator establishes a 34 
specific transcriptional and signaling network unrelated to that seen in normal cells, 35 
sustaining the expression of unique sets of genes required for AML growth and 36 
maintenance. 37 
  38 
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Acute myeloid leukemia (AML) is characterized by blocked myeloid lineage differentiation 39 
and accumulation of leukemic blast cells. AML is a highly heterogeneous disease caused by 40 
different types of mutations affecting signaling pathways as well as transcriptional and 41 
epigenetic regulators1-3. Recurrent mutations include loss of function mutations in 42 
transcription factors (TFs) controlling hematopoietic development, such as RUNX1, GATA2 43 
or C/EBPα4, and gain of function mutations in signaling molecules such as FLT3, KIT, JAK2 44 
and NRAS regulating inducible TFs such as NF-κB, STAT or AP-1 family members5,6,7. The 45 
most common FLT3 mutations are internal tandem duplications (FLT3-ITD), which give rise 46 
to a constitutively active growth factor receptor8,9 and often occur together with 47 
nucleophosmin1 mutations (NPM1). Another major group of mutations alters genes 48 
encoding epigenetic and chromatin regulators10,11 which play widespread roles in 49 
development and differentiation by controlling establishment, maintenance and extinction of 50 
lineage-specific gene expression programs. These include regulators of histone and DNA 51 
methylation such as MLL, EZH2, TET2, DNMT3A and IDH1/211-17. In normal cells, all 52 
common mutation targets cooperate to control the finely balanced gene expression changes 53 
essential for cell differentiation and lineage commitment.  54 
 TFs interact with defined target gene sequences and recruit epigenetic regulators to 55 
program specific chromatin states and mediate the coordinated activation or de-activation of 56 
cis-regulatory elements driving gene expression18,19. Distal cis-regulatory elements interact 57 
directly with promoter elements, an arrangement that is both dynamic and robust20,21. From 58 
global studies examining a few selected types of AML we know that gene expression 59 
patterns and the epigenetic landscape differ from normal cells22-27. However, how the 60 
disruption of specific TF activity leads to a specific pattern of aberrant chromatin 61 
programming and changes in gene expression in AML remained unclear. It was not 62 
established at the global level which cis-regulatory elements are affected in their activity in 63 
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different types of AML, how their activity is altered in patients carrying specific TF and 64 
signaling mutations or which factors maintain their transcriptional networks.  65 
 Here we addressed these questions by collecting transcriptome, digital footprinting 66 
and chromatin conformation capture data from purified leukemic blasts from AML patients 67 
with defined transcription factor and signaling molecule mutations and defined the 68 
components of AML subtype-specific regulatory circuitries. Our study comprises a 69 
comprehensive resource of the transcriptional networks of different AML subtypes, 70 
highlighting pathways required for tumour maintenance 71 
 72 
RESULTS 73 
AML subtypes adopt unique chromatin landscapes 74 
In order to examine how specific TF and signaling mutations alter the epigenome of AML, 75 
we purified leukemic blast cells from bone marrow or peripheral blood samples from AML 76 
patients (Fig. 1a). After determining the mutation status (Table S1), we selected a cohort of 77 
patients with defined mutations, which included: RUNX1 mutations affecting DNA-binding 78 
(D-type) or lacking the trans-activating domain (T-Type), t(8;21) translocations fusing the 79 
DNA binding domain of RUNX1 to the co-repressor ETO, inv(16) which fuses CBFβ to 80 
smooth muscle myosin heavy chain 11 protein, mutations of both alleles of the CEBPA gene 81 
whereby one mutation leads to loss of DNA-binding activity28 and FLT3-ITD with or without 82 
NPM1 mutations. We performed RNA-Seq (Supplementary Fig. 1a) and high read depth 83 
DNaseI-Seq (Fig. 1b) to map DNaseI hypersensitive sites (DHSs) on 29 samples 84 
comprising seven major groups, and at least one analysis on 12 additional samples, 85 
including mutations such as NRAS, CBL, JAK2, SRFS2, or inv(3) (Supplementary Table 1). 86 
One patient with Non-Hodgkin Lymphoma (NHL) carried a RUNX1 mutation (RUNX1-T-7). 87 
Samples were compared to CD34+ mobilized peripheral blood stem cells (PBSCs) from two 88 
healthy individuals and to cord blood (CB) CD34+ cells. To provide the community with a 89 
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data resource, we established an online database containing multiple data-sets including a 90 
genome browser (see Data Availability). 91 
 Unsupervised clustering revealed that distal DHSs formed different groups according 92 
to their mutations class (Fig. 1c). Samples with FLT3-ITD and/or NPM1 mutations 93 
represented one major group with sub-clusters for patients with NPM1 mutations or carrying 94 
two FLT3-ITD alleles, but excluding a FLT3-ITD patient carrying a RUNX1 mutation. DHSs 95 
from the t(8;21), inv(16) and CEBPA double mutant patients clustered as discrete groups 96 
within a larger group, indicating that these mutations affect similar pathways. Examples of 97 
these patterns can be seen in Supplementary Fig. S1b.  DHSs from patients with RUNX1 98 
mutations were more heterogeneous and clustered with the PBSCs and the inv(3) patients. 99 
The NHL (RUNX1-T-7) and the NPM1/RAS-3 patterns were unrelated to any of the others. 100 
We further validated our findings by analysing an independently derived published ATAC-101 
Seq data-set25, confirming that mutations in FLT3 underpin one major component of the 102 
clustering (Supplementary Fig. 2a). In contrast, the presence or absence of epigenetic 103 
mutations such as DNMT3A did not influence chromatin accessibility levels (Supplementary 104 
Fig. 2b) or gene expression (data not shown). Our mutation analyses showed no indications 105 
for the presence of confounding major sub-clones in purified undifferentiated AML cell 106 
populations, as mutations were present at close to either a 50% or a 100% allele frequency 107 
(Supplementary Dataset 1).  108 
 Unsupervised clustering analysis of RNA-Seq data from the same patients as well as 109 
direct comparisons between individual samples (Supplementary Figs. 1c, 2c) revealed 110 
strong correlations between mutation-specific chromatin landscapes and mutation-specific 111 
differential gene expression as exemplified by POU4F1 and FOXC1 where mRNA patterns 112 
correlated well with chromatin profiles (Supplementary Fig. 1d). We identified distinct 113 
patterns of expression for specific TF-encoding genes in different AML types 114 
(Supplementary Fig. 2d). For example, various homeo-domain gene family members 115 
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(HOX, NKX, IRX and PBX families) were up-regulated in the FLT3-ITD and NPM1-mutated 116 
patients. Our comparative analyses show that aberrant TFs and chronic signaling impose 117 
distinct mutation group-specific patterns of chromatin accessibility and gene expression, 118 
irrespective of the presence of other classes of mutations.  119 
  120 
AML-specific clustering of distal cis-regulatory elements 121 
We next examined the active cis-regulatory elements specific for each AML subtype by 122 
defining the union of all AML-specific DHSs as compared to CD34+ PBSCs and performing 123 
k-mean clustering to identify unique and common DHSs shared between patients, which 124 
identified 20 distinct DHS clusters (Fig. 2a). Less than half of these DHSs were found in any 125 
of the Corces et al. progenitor data ATAC-Seq sets25 and the percentage overlap varied 126 
substantially between clusters (range 2 – 40%; b). We verified mutation-specific clustering 127 
behaviour of our samples by comparing them with a recently published AML histone H3K27 128 
acetylation data set26 showing similar patterns for FLT3-ITD, RUNX1 and CEBPA double 129 
mutations (Supplementary Fig. 3d). We also defined mutation specific groups of 130 
deregulated DHSs that were shared between the specific members of each of the seven 131 
major mutation groups defined in Table S1 (Supplementary Figs. 4a and 4b) which were 132 
distributed between both the mutation-specific clusters and the shared clusters (Fig. 2b) and 133 
were associated with differentially expressed genes (Dataset S2). Again, the t(8;21), inv(16), 134 
and CEBPA  groups showed similar patterns whereby 914 upregulated DHSs were shared 135 
between the three groups (Supplementary Fig. 4a). The FLT3-ITD, FLT3- ITD/NPM1 and 136 
NPM1 mutation groups showed substantial overlap with 942 shared DHSs, and with only 137 
19% of these DHSs included in the 914 ITD/NPM1-specific group. These AML-specific 138 
patterns showed little similarity to normal myeloid differentiation as the majority of these 139 
specific sites were not up-regulated in GMPs relative to PBSCs (Fig. SN2b). 140 
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 The presence of specific DHSs strongly correlated with the up-regulation of their 141 
associated genes (Supplementary Dataset 3, Supplementary Fig.4c), as exemplified by 142 
two DHS at POU4F1 (Supplementary Fig 4d). Supplementary Fig 4e shows examples of 143 
AML type-specific up-regulated TF genes, and growth factor or receptor genes, which were 144 
associated with AML type-specific DHSs (Supplementary Data 4). The gene expression 145 
patterns of such genes were validated using publicly available data-sets (Supplementary 146 
Fig 5). 147 
 148 
AML-specific transcription factor binding patterns 149 
To identify TFs associated with the different chromatin patterns we analysed high-read depth 150 
DNaseI-Seq data using our Wellington digital footprinting algorithm29. Since closely related 151 
factors recognise identical sequences, compiling a non-redundant database of motifs 152 
(Supplementary table 2) and selected representative motifs encompassing each 153 
transcription factor family as defined in more detail on our web server (see URL list). 154 
Examples of footprints are depicted for NFI and ETS motifs at the MDFI locus in FLT3-155 
ITD/NPM1-mutated AML (Fig. 3a) and for RUNX, NFAT and C/EBP motifs at the C3AE1 156 
locus in t(8;21) and CEBPA-mutated AML (Supplementary Fig. 6a). The majority of AML 157 
type-specific DHSs within the 20 AML-specific DHS clusters contained footprints 158 
(Supplementary Fig. 6b). For validation, we compared RUNX motif footprints with publicly 159 
available RUNX1 ChIP data from our studies (FLT3-ITD/NPM124, t(8;21)30) and others 160 
(inv(16)31) (Supplementary Fig. 6c). Between 60% and 85% of footprinted RUNX motifs 161 
occurred in regions shown to bind RUNX1.  162 
 We next evaluated occupied motif enrichment in the 20 AML subtype-specific DHS 163 
clusters (Fig. 3b) which showed that motif occupancy patterns are highly AML type-specific. 164 
For example, the FLT3-ITD/NPM1-specific clusters 5 and 19 are enriched for occupied HOX, 165 
FOX/E-box and NFI motifs and correlate with up-regulation of FOXC1, NFIX and multiple 166 
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homeo-domain genes (Supplementary Fig. 2d). Occupied AP-1 motifs are enriched in 167 
multiple clusters (01, 05, 07, 12, 13, 18, 19), many of which in AML with signaling mutations. 168 
Because AP-1 factors mediate MAP kinase (MAPK) signaling this indicates wide-spread 169 
activation of this signaling pathway in FLT3-ITD AML24 and other AML types. Finally, we 170 
observed significant POU4F1 motif occupancy in clusters 02 and 20 containing samples 171 
from t(8;21) and CEBPA double mutant patients but nowhere else (Fig. 3b). POU4F1 is 172 
aberrantly expressed in t(8;21) cells32, but has so far not been linked to CEBPA double 173 
mutations. A similar differential occupancy pattern was seen when footprints were clustered 174 
according to mutation-specific groups of DHSs (Supplementary Fig. 6d). Note that motif 175 
occupancy of C/EBP motifs in AMLs with CEBPA double mutations showed no reduction in 176 
overall motif occupancy, suggesting compensation by other C/EBP family members.  177 
 To examine the position of transcription factor occupancy patterns within the 178 
hematopoietic hierarchy, we correlated the presence of footprints specific for AML-subtypes 179 
with accessible chromatin regions present in precursor cells (Fig 4)25. This analysis revealed 180 
unique factor occupancy patterns in AML cells compared to normal progenitors. For 181 
example, HOX motifs within open chromatin regions observed in HSCs, MPPs and MEPs 182 
are occupied in the FLT3-ITD/NPM1 and RUNX1 groups, but not in the t(8;21) group, 183 
indicating an early block in differentiation (see also Fig SN1b). Many of the samples, 184 
including NPM1, FLT3-ITD/NPM1 and t(8;21) cells, display high AP-1 motif occupancy which 185 
is normally only seen in monocytes. POU4F1 is expressed in HSCs, MPPs, MEPs and in 186 
CLPs25 and its binding motifs are occupied in t(8;21) and CEBPA double mutant cells, yet 187 
these AML cells also show strong occupancy of C/EBP motifs, which is normally a hallmark 188 
of GMPs and monocytes. In summary, our digital footprinting analysis shows (i) that each 189 
AML subtype employs a different combination of factors binding to elements shared with 190 
different types of precursor cells and that (ii) lineage unrelated expressed TFs such as 191 
FOXC1, NFIX and POU4F1 participate in such cooperation. 192 
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 193 
AML subtype-specific cis-element interactions 194 
The construction of gene regulatory networks relies on linking cis-regulatory elements to 195 
their respective promoters33. We therefore examined (i) whether the differential activity of 196 
cis-regulatory elements in AML sub-types resulted in the formation of alternate cis-element 197 
interactions, and (ii) which TF families were involved in such interactions, by employing 198 
promoter-capture chromosomal structure analysis (CHi-C)34. We analysed cells from relapse 199 
patient sample t(8;21)-1R (Supplementary table 1), which maintained a gene regulation 200 
network similar to the presentation sample t(8;21)-1 (Figs. 1c, Supplementary  Figs. 1c 201 
and 7a),  and a patient carrying a FLT3-ITD/NPM1 mutation (ITD/NPM1-2, Supplementary 202 
Table 1). We compared these data to a dataset derived from human CD34+ cells34. Intra-203 
chromosomal interactions did not differ at the global level (Supplementary Fig. 7b) and the 204 
organization into topologically associated domains (TADs) each containing the DHSs was 205 
unaffected by the type of AML (Supplementary Fig. 7c).  206 
 The proportion of DHSs involved in AML subtype-specific interactions varied 207 
between DHS-clusters (Supplementary Fig. 7d) and ~40% of all promoters showing 208 
differential interactions were associated with expressed genes (Supplementary Fig. 7e,f). A 209 
direct comparison between the CHi-C data from the two patients (Supplementary Fig. 7g) 210 
demonstrated that differential interactions (i) correlated with differential DHS patterns and 211 
that (ii) the expression of a differential set of genes with different GO terms (Supplementary 212 
Dataset 5) as exemplified by the KLF2 gene which is differentially expressed between FLT3-213 
ITD and t(8;21) and CD34+ cells (Supplementary Fig. 7h).  214 
 On average 80% of all DHSs mapped in the t(8;21) AML, the FLT3-ITD AML and the 215 
CD34+ cells participated in interactions (Supplementary Fig. 8a). An average of 17% of 216 
interactions were AML type-specific and not present in CD34+ PBSCs (Supplementary Fig. 217 
8b). To identify the TF families involved in regulating differential interactions we determined 218 
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the proportions of enriched occupied motifs in the DHSs underlying interactions 219 
(Supplementary Fig. 8c). These analyses suggest that hematopoietic TFs such as RUNX, 220 
ETS and C/EBP family members and AML subtype-specifically expressed TFs participate in 221 
differential interactions in both AML types, together with the AP-1 factor family. In the FLT3-222 
ITD AMLs this included HOX proteins and factors occupying FOX/E-box motifs. In the t(8;21) 223 
AMLs this included proteins binding to FOX and POU4F1 motifs.   224 
 225 
Differential interactions drive AML-specific gene expression  226 
 The majority of DHSs underlying interactions between the three data-sets and those 227 
of individual patients were shared with an average level of 80% overlap (Supplementary 228 
Fig. 8d), confirming that the global transcriptional network of related cells is highly 229 
related35,36. Sub-type-specific DHSs participating in interactions were enriched within related 230 
groups, but not within unrelated groups (Supplementary Fig. 8e), confirming that the two 231 
patients were representative for those groups. For both the FLT3-ITD/NPM1 and the t(8;21) 232 
sample the nearest promoter accounted for 65-74% of AML type-specific interactions 233 
associated with genes that are up-regulated compared to CD34+ cells (Fig. 5a). Similar 234 
results were seen for each of the 20 DHS clusters (Supplementary Fig. 8f). 235 
 To integrate differential interaction data, digital footprinting data and gene expression 236 
data, we assigned the respective DHSs to their interacting promoter as described in Fig 5b. 237 
GO-term and KEGG-pathway analyses of expressed genes in the two types of AML (Fig 5c-238 
f) revealed an AML subtype-specific core signature of genes being driven by specific cis-239 
regulatory elements (for an extended gene list see Supplementary Dataset 5). For both 240 
AML samples these included genes involved in regulating pro-inflammatory pathways. FLT3-241 
ITD cells also displayed an activated MAPK signaling signature whereas the t(8;21) 242 
signature also included RAP, RAS, PI3K and FOXO signaling genes. FOXO1 is already 243 
known to be part of the t(8;21) pre-leukemic maintenance program37. More than 50% of all 244 
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genes within these pathways were targets of RUNX1-ETO (Fig. 5g)30 thereby linking them to 245 
the actual driver mutation. A similar percentage of the genes within the FLT3-ITD/NPM1 246 
core pathway are bound by RUNX1 (Fig. 5g) which is up-regulated in FLT3-ITD24 247 
(Supplementary Dataset 5). Since ~83% of the DHSs involved in interactions in each of the 248 
3 samples (Supplementary Fig. 8g) were shared, we merged all three CHi-C data-sets to 249 
use this data to assign the DHS from the 20 clusters (Fig 2a) to their respective promoters. 250 
The remaining 17% of DHS were assigned to the nearest promoter. GO-term and KEGG-251 
pathway analyses of such genes (listed in Supplementary Dataset 6) again showed 252 
activation of genes connected with signaling processes, such as an inflammatory response, 253 
regulation of MAPK activity and cytokine regulation in all types of AML. 254 
 255 
AML subtypes display unique transcription factor networks 256 
Constitutive and inducible TFs form regulatory networks by interacting with their own and/or 257 
other regulatory genes35. Cancer cells maintain a stable regulatory network, implying that the 258 
expression of each network member is tightly controlled and remains in balance. 259 
Consequently, perturbation of the network components maintaining this balance may 260 
destabilize leukemic cells thus offering novel therapeutic options. We therefore combined 261 
footprinting, TF gene expression and where possible, CHi-C data to construct TF networks 262 
in normal CD34+ cells and the different AML subtypes by linking occupied binding motifs 263 
within TF genes to the specific TF families recognising these motifs. The TF families 264 
involved and the full network structure for each cell type without filtering can be studied in 265 
detail via the weblink (see URL). Comparison between the different AML subtypes and 266 
normal CD34+ cells identified interactions between TF sub-sets that were either shared 267 
between AMLs and CD34+ cells (Supplementary Fig. 9) or were subtype-specific (Fig. 6), 268 
These results suggest that the AP-1 family network is of regulatory relevance for all AML 269 
subtypes (Fig. 6b-g). POU4F1 and HLH family factors recognising MYC/MAX type E-boxes 270 
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formed prominent nodes in t(8;21) AML only, while HOX proteins, FOXC1, NFIX and the 271 
MAF family were exclusively highlighted in FLT3-ITD and NPM1 AML. Specific nodes and 272 
edges were also part of the normal precursor program (Supplementary Fig 9). For example 273 
the link between the C/EBP family and NFIL3 was shared between the FLT3-ITD/NPM1 274 
cells (Fig. 6f) and CD34+ PBSCs (Supplemental Fig. S9f). A detailed discussion of the 275 
different network structures and the role of different TF families with more examples can be 276 
found in Supplemental Notes. 277 
 278 
Transcription factors contributing to AML-specific growth  279 
We next validated the role of TFs forming network nodes by transducing  three different AML 280 
cell lines and primary FLT3-ITD AML cells with lentiviral vectors coding shRNAs targeting 281 
POU4F1 (specific for t(8;21)) or NFIX and FOXC1 (specific for FLT3-ITD). NFIX is known to 282 
play a role in myeloid lineage specification38 but has not been linked to specific mutation 283 
types. FOXC1 is an oncogene in its own right39 and overexpression is observed in AMLs 284 
with FLT3-ITD mutations24. However, NFIX and FOXC1 have not been linked to the 285 
maintenance of the FLT3-ITD AML. We transduced two distinct shRNA constructs per gene 286 
into FLT3-ITD and t(8;21) cell lines, significantly reducing the corresponding TF transcript 287 
and protein levels (Supplementary Fig 10a-f). Knockdown of POU4F1 (Supplementary 288 
Figs. 10a and d) inhibited the proliferation of t(8;21)-positive Kasumi-1 cells (Fig. 7a, 289 
Supplementary Fig. 10g), confirming our previous findings32. Expression of NFIX shRNAs 290 
(Supplementary Figs. 10b and e) impaired the proliferation of FLT3-ITD-positive MV4-11, 291 
but not FLT3-ITD-negative Kasumi-1 cells (Figs. 7b,c, Supplementary Fig. 10h,i). We next 292 
tested the effect of shRNA knock-down of these genes on the colony forming ability of 293 
CD34+ FLT3-ITD/NPM1 mutant patient cells and on CD34+ PBSCs. Both NFIX and FOXC1 294 
shRNA constructs reduced the colony forming ability of AML cells, but not that of normal 295 
CD34+ HSP cells (Figs. 7d, e). 296 
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 In addition to subtype-specific TFs such as POU4F1 or NFIX, our network analysis 297 
suggests that the AP-1 family is of general significance for all AML subtypes examined. AP-1 298 
is a heterodimer formed by members of the FOS, JUN, ATF, CREB and JDP families of 299 
transcription factors making it challenging to target by defined RNAi approaches. To this 300 
end, we transduced AML cells with an inducible version of a dominant negative FOS 301 
(dnFOS) protein40,41. Doxycyclin-mediated induction of dnFOS significantly inhibited 302 
proliferation of both t(8;21)-positive Kasumi-1 cells and FLT3-ITD expressing MV4-11 cell 303 
lines (Figs. 7f, g, Supplementary Fig. 10j, k)  and the colony-forming ability of primary 304 
CD34+ FLT3-ITD cells but not of CD34+ HPSCs (Figs. 7h,i, Supplementary Fig. 10l). 305 
 Finally, we examined the significance of AP-1 for leukemia propagation in vivo by 306 
transplanting either Kasumi-1 or MV4-11 cells expressing a doxycycline-inducible dnFOS 307 
into immunodeficient RG mice, followed by randomization into a doxycycline and untreated 308 
arm. In the case of Kasumi-1 transplantation, 6 out of 7 animals of the control group, but 309 
only 2 animals of doxycyclin-treated group developed granulosarcomas (Fig. 7j). Neither of 310 
the latter two tumours expressed dnFOS after DOX treatment (data not shown). Doxycycline 311 
treatment of mice transplanted with FLT3-ITD MV4-11 cells harboring the dnFOS transgene 312 
inhibited the development of leukemia while all untreated mice rapidly developed tumours 313 
and had to be sacrificed (Fig. 7k). Taken together, these findings demonstrate the 314 
significance of AP-1 for several AML subtypes and emphasize the potential of transcriptional 315 
network analyses to predict TFs crucial for malignant propagation. 316 
 317 
DISCUSSION 318 
In this study we defined how aberrantly expressed TFs and signaling molecules shape the 319 
epigenetic landscape of different sub-types of human AML. We show (i) that it is possible to 320 
use high-quality DNaseI footprinting analyses of purified AML blast cells to identify AML 321 
subtype-specific TF networks, (ii) that such TF networks point towards a dependency on 322 
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specific factors for leukemic growth and (iii) that the global activation of signaling pathways 323 
parallels a growth dependency on AP-1 activity in multiple types of AML. Our comprehensive 324 
integration of multi-omics data reveals a strong connection between leukemic classifier 325 
mutations, networks of TFs and signaling components in primary AML. Moreover, mapping 326 
of cis-element promoter interactions by CHiC enabled assigning the majority of genes of all 327 
analysed subtypes to their correct promoter. Different types of AML have previously been 328 
classified by their gene expression and DNA-methylation patterns42,43 revealing the 329 
existence of specific gene regulatory networks. Our work now defines these networks in 330 
detail, and convincingly proves that leukemic drivers determine the regulatory phenotype by 331 
establishing and maintaining specific gene regulatory and signaling networks distinct from 332 
normal cells. Induced and aberrantly expressed TFs are not bystanders, but are important 333 
for network maintenance and leukemic growth, thus highlighting novel therapeutic 334 
opportunities for targeted treatment. 335 
 The full set of target genes of RUNX1-ETO in t(8;21) is known and the t(8;21) 336 
specific epigenome and TF binding pattern has been extensively characterized44. Multiple 337 
target genes relevant for the maintenance of the leukemogenic state have been identified, 338 
including FOXO1, UBASH3B, POU4F1, and LAT2 together with the members of the 339 
RUNX1-ETO complex 22,32,37,45-47 and our current comparative study has identified multiple 340 
new network components. However, for the other types of AML, in particular for the FLT3-341 
ITD such knowledge was not available. Here, we identified a number of signaling and 342 
transcriptional components distinguishing FLT3-ITD from normal blasts and from other types 343 
of AML, comprising a rich resource for combinatorial therapy approaches. We examined the 344 
contribution to leukemic growth for two genes with AML subtype-specific activity (NFIX and 345 
FOXC1) and showed that their elimination resulted in reduced growth and colony forming 346 
ability of AML but not normal cells, confirming that AML maintains an aberrant transcriptional 347 
network required for survival.  348 
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 The AP-1 factor family plays an important role in many types of tumours48 and our 349 
study shows that it is of major importance for AML. FLT3-ITD MV4-11 cells have abundant 350 
levels of nuclear AP-1, and FLT3-ITD target genes such as CCNA1 are suppressed by 351 
MAPK  inhibitors in these cells24. We have recently shown that JUN scores highly in a siRNA 352 
dropout screen examining the requirements for tumour development in t(8;21) AML 353 
(Martinez-Soria et al., in press). FOS plays an important role in the resistance against BCR-354 
ABL inhibition in CML by activating compensatory signaling pathways49. Since several 355 
growth factor and stress signal cascades feed into AP-1, a targeted inhibition of all AP-1 356 
binding may avoid resistance via rewiring of signalling pathways. 357 
 In the classical mechanism of two-step leukemogenesis a mutation altering a 358 
differentiation trajectory cooperates with signaling mutations directing leukemic growth10,11. 359 
Mutations in TFs and epigenetic regulators setting up the epigenetic landscape upon which 360 
TFs act, fall into the first category while the FLT3-ITD mutation falls into the second. 361 
However, these distinctions are becoming blurred as from the viewpoint of gene regulation, 362 
growth factor receptors strongly influence transcriptional activity via inducible TFs, as 363 
exemplified by AP-1 family members. These factors play a dominant role in driving the 364 
differentiation trajectory as they display an AML sub-type specific occupancy signature that 365 
is uninfluenced by the presence or absence of epigenetic regulator mutations (in this case 366 
DNMT3A)24. This is not to say that mutations in epigenetic regulators do not influence the 367 
developmental trajectory of AML and clinical outcomes, as shown in CBF AML50 since AML 368 
cells with such mutations acquire an altered DNA methylation landscape that is likely to 369 
influence TF binding51. However, our data show that leukemic phenotype and self-renewal of 370 
different types of AML are defined by differentially activating a multitude of different and 371 
often lineage-unrelated signaling pathways and by expressing lineage-unrelated TFs. From 372 
the viewpoint of finding therapeutic targets, identifying such mutation-specific pathways will 373 
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offer an opportunity to eliminate their specific maintenance program by targeting multiple 374 
pathways simultaneously. Our study provides a first step towards this goal.  375 
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METHODS  376 
Patient samples and PBSC cell processing 377 
Human tissue was obtained with the required ethical approval from the NHS National 378 
Research Ethics Committee. AML and PBSC samples used in this study were either surplus 379 
diagnostic samples, or were fresh samples obtained with specific consent from the patients. 380 
AML samples were obtained from either (i) the Haematological Malignancy Diagnostic 381 
Service (St James’s Hospital, Leeds, UK, (ii) the Centre for Clinical Haematology, Queen 382 
Elizabeth Hospital Birmingham, Birmingham, UK, (iii) the West Midlands Regional Genetics 383 
Laboratory, Birmingham Women’s NHS Foundation Trust, Birmingham, UK, or from iv) 384 
Erasmus University Medical Center, Rotterdam, The Netherlands. Mononuclear cells were 385 
purified on the same day that they were received, and in most cases also directly further 386 
purified using either CD34 or CD117 (KIT) magnetic antibodies, as previously described 24. 387 
For some samples with greater than 92% blast cells the column purification was not 388 
performed. Mobilized PBSCs were provided by NHS BT, Leeds, and NHS BT, Birmingham. 389 
Mutation detection 390 
Mutated genes identified in each patient are summarized in Supplementary Table 1, 391 
together with the age, gender and white blood cell count for each patient.  Mutations were 392 
identified by one of two different methods. The first batch of patients were assayed by 393 
targeted exon sequencing of 55 cancer-associated genes using 1212 pairs of previously 394 
defined PCR primers 24 for amplification using a RainDance Technologies platform. The 395 
mutation sequence data from this screen was analyzed using algorithms to detect either (i) 396 
nucleotide variants using the Genome Analysis Toolkit (GATK) 52 or insertions and deletions 397 
using Pindel 52. Mutations were also screened against the COSMIC database of previously 398 
observed mutations (link see URL section). Subsequent samples were assayed using the 399 
Illumina Trusight myeloid panel of primers and processed by approaches similar to those 400 
used for the first batch. All identified mutations are listed in Table S1. Some of these patients 401 
 18
were also included in a previous publication from our laboratory, using different patients 402 
identification codes 24 to those used in the current study. 403 
Cell lines 404 
Cell lines were cultured in an incubator at 370C in GIBCOTM 1640 RPMI + GlutamaxTM 405 
medium supplemented with 10% heat inactivated fetal calf serum (GIBCO), 100 U/ml 406 
Penicillin, 100 mg/ml Streptomycin. 407 
Growth curve measurements  408 
250000 MV4-11 or Kasumi-1 cells were cultured in RPMI supplemented with 10 % fetal calf 409 
serum, 2mM L-Glutamine, 100 U/ml penicillin and 100 mg/ml streptomycin. Cells were 410 
counted with Trypan Blue exclusion and split every 3 days to maintain them in the log phase 411 
of growth. For the inducible dnFOS, cells were counted and split every 2 days and 1.5 µg/ml 412 
of doxycycline was added. 413 
Co-culture of Primary Cells with MS-5 feeders 414 
Primary cells were maintained in co-culture with MS-5 cells 53 Briefly, cells were cultured in 415 
LTC medium (α-minimum essential medium (Lonza) supplemented with heat-inactivated 416 
12.5% fetal calf serum (Gibco), heat-inactivated 12.5% horse serum (Gibco), penicillin and 417 
streptomycin, 200 mM glutamine, 57.2 μM β-mercaptoethanol (Sigma) and 1 μM 418 
hydrocortisone; (Sigma) supplemented with 20 ng/ml IL-3, granulocyte colony-stimulating 419 
factor (G-CSF) and thrombopoietin (TPO) in flasks pre-coated with MS-5 cells. 420 
Lentiviral transduction and shRNA treatment  421 
LEGO-iG-shRNA were generated by cloning shRNAs (Table S3) into the LEGO-iG vector54. 422 
LEGO-iG-dnFOS was generated by cloning the dnFOS insert, originally generated by 423 
Charles Vinson (National Cancer Institute, Bethesda, USA 40 into the LEGO-iG backbone. 424 
Inducible dnFOS was cloned into a pENTR backbone and then using Gateway Cloning to 425 
insert that into the Tet-on plasmid pCW57.1 (David Root, Addgene plasmid #41393). 426 
Backbone vectors LEGO-iG and Inducible dnFOS then used to generate lentiviral particles 427 
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using packaging and envelope genes on four separate plasmids: TAT, REV, GAG/POL and 428 
VSV-G55. 429 
For virus production, 293T Human Embryonic Kidney cells were cultured in Dulbecco’s 430 
Modified Eagle Medium supplemented with 10 % fetal calf serum, 2mM L-Glutamine, 100 431 
U/ml penicillin, 100 mg/ml streptomycin and 0.11 mg/ml Sodium pyruvate; and were seeded 432 
to achieve 70-80% confluency at time of transfection. HEK293T cells were transfected using 433 
the calcium phosphate co-precipitation of the five-plasmids (LEGO-iG with TAT, REV, 434 
GAG/POL and VSV-G) at a mass ratio of 24 μg : 1.2 μg : 1.2 μg : 1.2 μg : 2.4 μg per 150 435 
mm diameter plate of cells. Viral supernatant was harvested after 24 h and subsequently 436 
every 12 h for 36 h prior to concentration with Centricon Plus 70 100 kDa filter (Millipore, 437 
USA), using the manufacturer’s instructions. Concentrated viral particles were stored at 4 °C 438 
prior to lentiviral transduction. Cell lines were transduced with concentrated virus in the 439 
presence of 8 μg/ml polybrene by spinoculation at 1500 xG for 50 min. After 12 – 16 h 440 
incubation at 37 °C viral media was exchanged for fresh media. Cell sorting by FACS was 441 
performed to isolate GFP+ cells 3 days after transduction. 442 
Primary cell samples were defrosted 24 h prior to transduction and co-cultured with MS-5 443 
feeder cells in LTC medium. 6 well non-tissue culture treated plates were coated with 24 444 
μg/ml retronectin (Takara Clontech) for 2 h prior to blocking with 2% BSA PBS for 30 min. 445 
The blocking buffer was washed off with HBSS (Gibco) containing 2.5% HEPES. 1 ml viral 446 
concentrate was applied to the retronectin coated plate by centrifugation at 2000 xG for 45 447 
minutes, after which the concentrated viral supernatant was refreshed and the centrifugation 448 
repeated. Primary cells suspended to a concentration of 1 x 106 cells/ml in the remaining 449 
viral supernatant; supplemented with 20 ng/ul G-CSF, IL-3, TPO and 8 μg/ml polybrene, 450 
were then added to the plate and transduced by spinoculation at 1500 xG for 50 min. After 451 
12 – 16 h incubation at 37 °C viral media was exchanged for fresh media. Cell sorting by 452 
FACS was performed to isolate GFP+ cells 3 days after transduction. 453 
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Colony Formation Assays of Primary Cells 454 
Colony formation assays were performed on sorted cells by seeding at 2500 cells/ml in 455 
Methocult Express (Stem Cell Technologies). After 14 days colonies were counted.  456 
Animal experiments 457 
Immunodeficient Rag2−/−Il2rγ−/−129×Balb/c (RG) mice were housed in the Comparative 458 
Biology Centre (Newcastle University) under specific pathogen free conditions. All animal 459 
work was conducted in accordance with Home Office Project License PPL60/4552 by 460 
researchers who had completed approved Home Office training and held current Personal 461 
Licenses under the Animals (Scientific Procedures) Act 1986. Kasumi-1 pCW57.1-dnFOS 462 
cells were intrahepatically injected into 14 newborn (2 days old) RG mice at a cell dose of 463 
2.5x105 cells/mouse as described previously (Martinez Soria et al., 2009). Twelve days later, 464 
mice were randomized into two treatment groups, one given doxycycline 50 mg/kg three 465 
times per week intraperitoneally in an unblended fashion till the experimental endpoint. MV4-466 
11 pCW57.1-dnFOS cells were intrafemorally injected into RG mice at a cell dose of 5x105 467 
cells/mouse followed by randomization into two groups. For the dox group doxycycline was 468 
added at a concentration of 2 mg/ml for the initial 3 days and at 0.2 mg/ml subsequently to 469 
drinking water containing 2% sucrose. Controls were given water containing 2% sucrose. 470 
Animals were humanely killed upon clinical signs of illness or at defined experimental 471 
endpoints. 472 
RT- qPCR 473 
RNA was extracted using the Machery-Nagel Nucleospin kit. 1μg RNA was used to make 474 
cDNA with 0.5μg OligoDT primer, Murine Moloney Reverse Transcriptase and RNase 475 
Inhibitor (Promega, USA) according to manufacturer’s protocol.  RT-PCR was performed 476 
using Sybr Green mix (Applied Biosystems, UK), at 2x dilution.  Primers were used at 477 
100nM concentration. A 7900HT system (Applied Biosystems, UK) was used to perform 478 
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qPCR. Analyses were performed in technical duplicates using a standard curve derived from 479 
the untreated cell line. 480 
Western Blotting 481 
Protein lysates from cell lines were analyzed by Western blot. Relevant primary antibodies 482 
against FOXC1 (Cell Signaling Technology - #8758), NFIX (Invitrogen - #PA5-31234), 483 
POU4F1 (Santa Cruz Biotechnology – sc-8429) were used to detect target genes and 484 
GAPDH (mouse αGAPDH – Abcam – ab8245; rabbit αGAPDH – Cell Signaling Technology 485 
– 2118L) was used as a housekeeping gene. Secondary antibodies mouse anti-rabbit HRP 486 
(Santa Cruz Biotechnology – sc-2054) and goat anti-mouse HRP (Jackson 487 
ImmunoResearch – 115-035-062) enabled detection and quantifications by densitometry 488 
using Imagelab software and a GelDoc imager.  489 
Statistical analysis of validation experiments 490 
Validation experiments were performed in triplicate (n=3) where each replicate represents a 491 
separately transduced cell line or primary cell sample cultured and analyzed independently. 492 
The exception are the in vitro inducible dnFOS cell line experiments where each replicate 493 
represents a separate culture of a clone stably expressing the dnFOS peptide in order to 494 
avoid variations in the degree of expression. The significance of differences in colony 495 
counts, doubling time, mRNA expression and cell concentrations at individual time points on 496 
growth curves were calculated using Student’s t-test where n=3 using 4 degrees of freedom, 497 
t values between significantly different groups (p<0.05) were all greater than t=3.2. 498 
Standard error bars on graphs show standard error of the mean: ̅ݔ ±  ఙ√௡ . 499 
The tumor mass of mice transplanted with Kasumi-1 pCW57.1-dnFOS with and without dox 500 
was analyzed using a Mann-Whitney test as the distribution of data was not normal. This 501 
experiment was performed n of 7 engrafted mice in each group (p=0.0326, Mann-Whitney U 502 
= 8.5. The survival curve of mice engrafted with MV4-11 pCW57-dnFOS with and without 503 
dox was analyzed using a Kaplan-Meier plot (n=5 engrafted mice) using a Mantel-Cox Chi-504 
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square test (Chi square = 8.097, df=1, p=0.0044) and yielding a Mantel-Haenszel hazard 505 
ratio of 14.08. 506 
RNA-Seq library preparation 507 
RNA was extracted and analyzed from purified AML cells as previously described 23  508 
DNaseI-Seq  509 
DNaseI digestions of permeabilized cells were performed as previously described56. Briefly, 510 
live cells were added directly to a solution of DNaseI (DPFF, Worthington) in dilute Nonidet 511 
P40, digested for 3 min at 22oC, and the reactions then terminated by addition of SDS to 512 
0.5%. DNaseI was typically used in the range of 2-6 μg/ml using a final 1.5 x 107 cells/ml. 513 
DNaseI-Seq libraries were then prepared and validated essentially as previously described 514 
30. Libraries were run on Illumina sequencers. 515 
Promoter capture HiC (CHi-C) from patient AML blasts 516 
AML cells from patient peripheral blood were first purified by density gradient centrifugation 517 
(Lymphoprep™) and then using CD34 antibody coupled beads. 5× 107 t(8;21) blasts (patient 518 
t(8;21)-1R) and FLT3-ITD/NPM1 blasts (patient ITD/NPM1-2) were fixed in 37 ml of RPMI-519 
1640 supplemented with 15% FBS and 2% formaldehyde for 10 minutes at room 520 
temperature. 6 ml of 1M glycine (0.125 M final concentration) was added to quench the 521 
reaction and cells were incubated at room temperature for 5 min, followed by 15 minutes on 522 
ice before pelleting the cells at 4 °C and washing them in ice cold PBS. Each sample was 523 
flash frozen in liquid nitrogen, and stored at −80 °C. Cells were lysed in a tight dounce 524 
homogeniser (ten cycles) with 3ml of cold lysis buffer (10 mM Tris-HCl pH 8, 10 mM NaCl, 525 
0.2% Igepal CA-630, one tablet protease inhibitor cocktail (Roche complete, EDTA-free, 526 
11873580001)). Cells were left on ice for five minutes then homogenised another ten times. 527 
The lysed cells, in 3 ml lysis buffer, were added to 47ml of lysis buffer and incubated on ice 528 
for 30 minutes with occasional mixing. Chromatin was pelleted and resuspended in 1ml of 529 
1.25x NEBuffer 2 and split into four. Each sample was then pelleted at 1000 rpm and 530 
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resuspended in 358 µl of 1.25x NEBuffer 2. 11 µl 10% SDS was added and each tube was 531 
incubated at 37°C for 60 minutes, rotating at 950 rpm. Samples were mixed by pipetting up 532 
and down every 15 minutes. SDS was quenched with 75µl 10% Triton X-100 and incubated 533 
at 37˚C for 60 minutes. HindIII digestion, biotinylation, ligation, crosslink reversal, promoter 534 
capture and library preparation was performed exactly as described in34.  535 
DNaseI-Seq data analysis 536 
Alignment: DNaseI-seq sequences from all experiments were mapped onto the reference 537 
human genome version hg38, with Bowtie version 2.3.157,24 using default parameters.  Low 538 
quality reads were trimmed prior to the alignment and the quality control (QC) statistics for 539 
the samples were obtained using FastQC tools. Reads that were aligned to unique 540 
chromosomal positions were retained. 541 
Peak calling. DNaseI Hypersensitive Sites (DHSs) were called with MACS2 using callpeak 542 
function (nomodel, call-summits and q= 0.005 parameters)58.  DHSs were allocated to genes 543 
and to the gene promoter if it was within 2kb of the gene transcription start site (TSS), and 544 
as distal otherwise. Overlaps between DHSs peaks were defined by requiring the summits of 545 
two peaks to lie within +/-200 bp. 546 
DNaseI-Seq peak set definition: To define a common set of coordinates covering all of the 547 
significant distal DHSs investigated in this study, we merged all of the individual DNaseI-Seq 548 
reads for all of the AML samples assayed by DNaseI-Seq. This data set was then used to 549 
define the peak summits of 128,864 distal peaks, excluding promoters, which were detected 550 
in the merged data. This approach was designed to maximize the precision and sensitivity of 551 
the peak detection, allowing us to generate a single set of peak coordinates that (i) included 552 
all the regions where peaks might be found, thereby reducing the level of false negatives, 553 
and  (ii) greatly diminished the number of false positives. The DNA read counts were then 554 
determined for 400 bp windows centered on each peak for each AML sample and for the 555 
PBSC samples. To account for the different number of reads in each of the samples; the 556 
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read counts were initially normalized for total read depth using DEseq2 59. Because most of 557 
our individual DNaseI-Seq data sets encompassed in the range of 25,000 to 40,000 558 
significant distal DHSs, we further normalized the values obtained on the basis of the 559 
midpoint (12.5 percentile) of the top 25% of peaks (32,216 peaks).  560 
Mutation-specific DNaseI-Seq peak set definition: We determined the average log2 561 
values for 7 distinct groups of AMLs that carried the same specific mutations in key 562 
regulators, and which shared similar patterns of DHSs based on the DHS clustering analysis. 563 
The samples included in each group are color-coded and listed in order in Table S1 for AML 564 
samples with the following mutations: (i) 3 samples with FLT3-ITD but not NPM1 (#1 to 3), (ii) 565 
6 samples with FLT3-ITD and NPM1 (# 1 to 6), (iii) 2 samples with NPM1 but not FLT3-ITD 566 
(# 1 and 2), (iv) 4 samples with t(8;21) (1 to 4), (v) 3 samples with inv(16) (# 1 to 3); (vi) 6 567 
samples with RUNX1 or RUNX1 and CEBPA (1 to 6), and (vii) 3 samples with 2 CEBPA 568 
mutations (#1 to 3). To define mutation-specific subsets of specific DHSs, we identified 569 
peaks where the average log2 value both was at least 64 and at least 3-fold higher than in 570 
PBSCs. Downregulated DHSs are defined as being at least 3-fold less than in PBSCs. 571 
Samples were not included in these 7 specific groups in cases where, for example, 2 copies 572 
of the FLT3-ITD mutation were present, the NPM1 mutation was paired with a NRAS instead 573 
of the FLT3-ITD, RUNX1 mutations were paired with a JAK2 mutation, or where only a 574 
single CEBPA allele was mutated. 575 
Clustering of DNaseI-Seq data: Clustering of DNaseI-seq samples was carried out using 576 
the merged distal DHSs. The number of reads that mapped to these DHSs was counted in a 577 
400bp window centered on the DHS summit, and subsequently normalized to total sample 578 
size using DEseq2 59. Pearson correlation coefficients were then calculated for each pair of 579 
samples using the log2 of the normalized read counts, and then hierarchically clustered 580 
using Euclidean distance and complete linkage clustering of the correlation matrix in R. 581 
For further analysis methods see Supplementary Material. 582 
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RNA-seq data analysis 583 
RNA-Seq reads were aligned to the human genome hg38 build with STAR60 using ENCODE 584 
recommend parameters. Separate density profiles for the positive and negative strand were 585 
generated using bedtools. Cufflinks61 was used to calculate the expression values as 586 
Fragments Per Kilobase per Million aligned reads (FPKM) from the aligned RNA-seq data. 587 
Mutation-specific group’s gene-wise expression values were obtained using the cuffdiff 588 
function of cufflinks. The correlation between any two AML samples was obtained as the 589 
Pearson correlation coefficient of expression values over all genes. A correlation matrix was 590 
thus generated for all the samples and hierarchically clustered to study the relationship 591 
among samples as given in Figure S1C. Smooth scatter plots were generated in R. For 592 
further analysis methods see Supplementary Material. 593 
Promoter Capture HiC data analysis 594 
The CHi-C paired-end sequencing reads from ITD/NMP1-2 and t(8;21)-1R patients and a 595 
publically available CD34+ dataset (accession numbers ERR436032 and ERR436025)  were 596 
put through HiCUP pipeline62. The raw sequencing reads were separated and mapped 597 
against the human genome (hg38). The reads were then filtered for experimental artefacts 598 
and duplicate reads, and then re-paired. Statistically significant interactions were called 599 
using GOTHiC package63 and HOMER software. This uses a cumulative binomial test to 600 
detect interactions between distal genomic loci that have significantly more reads than 601 
expected by chance, by using a background model of random interactions. This analysis 602 
assigns each interaction with a p-value, which represents its significance. Differential 603 
interactions were determined with HOMER64 for t(8;21) using FLT3-ITD or CD34+ as 604 
background and FLT3-ITD using t(8;21) or CD34+ as a background. A difference with a p-605 
value of less than 0.1 was deemed to be significant 606 
Transcription Factor Gene Regulatory Network Construction 607 
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We identified a subset of 310 transcription factor (TF) genes that are expressed in one or 608 
more of our AML samples. The gene names for transcription factors in human were obtained 609 
from AnimalTFDB65. The 310 TFs were considered as nodes and the nodes coloured 610 
according to their expression values at each AML subtype (Fig 6, Supplementary Fig 9 611 
and Fig SN5). Node border colour signifies whether the gene is up-regulated, down-612 
regulated or invariant base on a 2-fold-change compared to CD34+ cells. The node border 613 
type indicates whether a gene is differentially expressed in one AML subtype as compared 614 
to other subtypes. A directed edge from TFa to TFb indicates motif binding of a TFa to the 615 
locus of the TFb and the edge is prominently displayed if TFa binds to the locus at that stage. 616 
The edge is classified and colour coded according to the significant of motif count 617 
enrichment.  618 
Motif count enrichment for TFs network: Initially footprints for each AML subtype were 619 
identified by using the Wellington algorithm29 and were annotated to their related promoter 620 
using CHi-C data where possible. Motif search within footprint coordinates where performed 621 
using HOMER64.  The number of motifs per TF gene were counted and the significance of 622 
motif enrichment was identified using bootstrapping on random sampling, a random set of 623 
mapped motif were extracted from all union footprinted motif of all AML subtypes and the 624 
CD34+ cells. After 1000 iterations the mean, standard deviation and the z-scores are 625 
computed. Motif (TFa) is linked to gene (TFb) with positive Z-score values only.  626 
Motif count enrichment for up-regulated TFs: The correlations (re) between all TF genes 627 
based on FPKM values from the RNA-seq analysis were identified and the correlations (rm) 628 
between all TF genes based on motif count binding were identified. The correlation 629 
coefficients were z-transformed using Fisher Z-transformation with “FisherZ” function in R.  630 
The average of the transformed z-scores of both gene expression and motif were 631 
transformed to correlation (r). All TF genes with a correlation coefficient equal or greater 632 
than a cut-off of 0.3 were considered. Then for each AML cell type, the differentially 633 
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expressed TF genes among these correlated genes were identified. First those of each AML 634 
subtype as compared to CD34+ cells and second those of all AML subtypes compared to the 635 
average expression of other subtypes including CD34+ cells.  Up-regulated genes with a 2-636 
fold-change in expression compared to CD34+ cells or compared to other AMLs were 637 
considered to construct the network. Motif enrichment for the correlated and up-regulated TF 638 
genes and edges were identified as described above. 639 
List of used position weight matrices: A description of how the motifs were curated can 640 
be found in the legend of Table S2. 641 
 642 
Data availability 643 
Raw data have been deposited at GEO under the accession number GSE108316.  644 
 645 
URLs 646 
Processed data will be available from our webserver:  647 
http://bioinformatics-bham.co.uk/tfinaml/ 648 
Other links: 649 
http://cancer.sanger.ac.uk/cosmic/ 650 
 651 
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Figure Legends 838 
 839 
Figure 1: Different types of AML adopt unique transcriptome and chromatin 840 
landscapes. (a) Experimental strategy. (b) UCSC Genome browser tracks of DNaseI-seq 841 
mapping in purified AML cells. (c) Hierarchical clustering of Pearson correlation coefficients 842 
of DNaseI accessible sequences from all patient samples with normalized read counts of 843 
DNaseI-Seq data for the different classes of mutations (left panel), right panel: list of 844 
mutations in cells from each patient 845 
 846 
 847 
Figure 2: AML-specifically active cis-regulatory elements cluster into common and 848 
unique chromatin landscapes. (a) Heatmap depicting unsupervised K-mean clustering of 849 
the DNaseI-Seq log2 signals seen in each AML specific distal DHS peak in each AML 850 
sample compared to PBSCs. Clustering was done only on rows (DHS peaks) while samples 851 
were ranked based on the clustering in Fig, 1c. The diagram on top of the heatmap shows 852 
the DHS peak population used for clustering. (b) Binary heatmap showing the overlap 853 
between the clusters from A and the DHSs of the 7 mutation classes which are deregulated 854 
compared to CD34+ PBSCs as described in Supplementary Fig 4a.  855 
 856 
Figure 3: AML-specifically active cis-regulatory elements display AML type-specific 857 
transcription factor occupancy patterns. (a) UCSC browser screen shot of the MDFI 858 
locus zooming in on an AML type-specific DHS (box) with occupied NFI, ETS and RUNX 859 
sites. (b) Heatmap depicting the degree of motif enrichment after hierarchical clustering of 860 
motif occupancy in each of the 20 AML DHS clusters. Enrichment score was calculated by 861 
the level of motif enrichment in all the footprints of all high read-depth samples for each 862 
cluster, as compared to union of footprints in all experiments. 863 
 37
 864 
Figure 4: AML cells show occupied motif patterns unrelated to normal progenitor 865 
cells.  Enrichment analysis of footprinted motifs in AML subgroups which overlap with 866 
ATAC-Seq peaks present in precursor cells 25.  867 
 868 
Figure 5: Capture HiC shows differences in locus-specific cis-regulatory interactions 869 
between different types of AML and normal cells. (a) Percentage of up- and down-870 
regulated genes with differential interactions from the FLT3-ITD and the t(8;21) compared to 871 
CD34+ PBSCs. The bar figure shows also the percentage of the common genes for the 872 
FLT3-ITD and the t(8;21), the number of differentially expressed genes (DEG) is shown on 873 
top of each bar. (b) Flow diagram showing the steps for identification of differential 874 
interactions and the downstream analysis. (c) Top enriched GO terms for the up-regulated 875 
genes of the FLT3-ITD compared to CD34+ PBSCs as outlined in (a). (d) Network diagram 876 
of top KEGG pathways for the up-regulated genes of the FLT3-ITD compared to CD34+ 877 
PBSCs as outlined in (a). (e) Top enriched GO terms for the up-regulated genes of the 878 
t(8;21) compared to to CD34+ PBSCs shown as outlined in (a) Network diagram of top 879 
KEGG pathways for the up-regulated genes of the t(8;21) compared to CD34+ PBSCs as 880 
outlined in (b). (h): Percentage of RUNX1-ETO and RUNX1 targets amongst up-regulated 881 
genes with differential interactions, the exact number of genes is shown above the bars. 882 
 883 
Figure 6: Identification of transcription factor networks driving the expression of AML 884 
type-specific up-regulated TF genes  885 
(a) Outline of analysis strategy. (b) t(8;21)-specific TF network, (c) CEBPA(x2)-specific TF, 886 
(d) Inv(16) specific TF network, (e) Mutant RUNX1-specific TF network, (f) FLT3-ITD/NPM1 887 
specific TF network, (g) NPM1-specific TF network 888 
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Factor families binding to the same motif as shown in Supplementary table 2 form a node 889 
contained within a circle. Arrows going outwards from the entire node highlight footprinted 890 
motifs in individual genes generated by any member of this factor family whereby the 891 
footprint was annotated to the gene using the CHiC data where possible, otherwise to the 892 
nearest gene. For selected nodes, the name of the underlying motif is highlighted in large 893 
letters. The expression level (FKPM) for the individual genes is depicted in white (low)/red 894 
(high) colour. An orange smooth ring around the circle indicates that this gene is specifically 895 
up-regulated in this type of AML compared to CD34+ PBSCs and/or other AML types, a 896 
dotted circle indicates a gene that is up-regulated as compared to CD34+ cells. Genes 897 
without outgoing arrows due to a lack of know binding motifs are highlighted by their octagon 898 
shapes. 899 
 900 
7: Identification of AML type-specific TFs required for maintaining leukemic growth 901 
and colony forming ability. 902 
(a - c) Scatter plot showing the growth curves of (a) Kasumi-1 cells after transduction with 903 
shPOU4F1 and (b) of MV4-11 cells after transduction with shNFIX. (d, e) Histogram showing 904 
the number of colonies formed by a FLT3-ITD+ primary AML cell samples (d) or PBSCs (e) 905 
after transduction with shRNA targeting FOXC1, NFIX or a mismatch control. (f) Scatter plot 906 
showing the growth curve of Kasumi-1 cells transduced with either a doxycycline-inducible 907 
dominant negative FOS or an empty vector control (right panel) with and without 1.5 mcg/ml 908 
doxycycline. (g) Dot plots showing the growth curve of MV4-11 cells transduced with either a 909 
doxycycline-inducible dominant negative FOS or an empty vector control (right panel) with 910 
and without 1.5 μg/ml doxycycline. (h,i) The expression of a dominant negative FOS causes 911 
a reduction in the colony forming ability of CD34+ FLT3-ITD+ primary AML cells (H) but not 912 
CD34+ PBSCs (i). All experiments were performed in triplicate and significance tested using 913 
a two-tailed Student’s t-test (n=3) with * p<0.05, **p<0.01 in both samples compared to the 914 
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mismatch control where indicated. Error bars show standard error of the mean. (j) 915 
Granulosarcoma formation in RG mice by Kasumi-1 expressing a doxycycline-inducible 916 
dnFOS. dnFOS was induced by intraperitoneal injection of doxycycline. (k) Survival curve for 917 
RG mice transplanted with MV4-11 cells expressing doxycycline-inducible dnFOS. dnFOS 918 
was induced by adding doxycycline to the drinking water. The control group did not develop 919 
any tumors during the observed time frame while all mice of the induced group had to be 920 
sacrificed.  921 
  922 
 923 
 924 
Patient code Signalling NPM1 Chrom RUNX Other mutations
RUNX1-T/JAK-2 JAK2 RUNX1 TET2x2,TP53
RUNX1-D/JAK-1 JAK2 tri(21,9) RUNX1 IDH2, SRSF2
RUNX1-D-5 RUNX1 IDH1, BCORL1x2, SRSF2x2
RUNX1-T/CEBPA-6 NRAS tri(8) RUNX1 CEBPA, EZH2
RUNX1(x2)-D&T-4 RUNX1x2 DNMT3A, IDH2, SRSF2
RUNX1-DT-3 RUNX1
RUNX1-DT/CEBPA-2 FLT3-ITD RUNX1 CEBPA, WT1x2, SF3B1, TP53
RUNX1-DT-1 FLT3 tri(13) RUNX1 CREBBP, DNMT3A, SF3B1 
PBSC-1
PBSC-2
inv(3)/RAS-1 NRAS inv(3) GATA2, SF3B1
inv(3)/CBL-2 CBL inv(3) SF3B1
ITD/NPM1-4 FLT3-ITD NPM1 GATA2, DNMT3A
ITD-1 FLT3-ITD DNMT3A, TET2x2, BCOR, TP53
ITD/NPM1-5 FLT3-ITD NPM1 DNMT3A, BCOR
ITD-3 FLT3-ITD DNMT3A
ITD/NPM1-6 FLT3-ITD NPM1 WT1, DNMT3A, TET2, PHF6
ITD-2 FLT3-ITD tri(13) DNMT3A, TET2
ITD/NPM1-1 FLT3-ITD NPM1 WT1, DNMT3A 
ITD/NPM1-3 FLT3-ITD NPM1
ITD/NPM1-2 FLT3-ITD NPM1
NPM1-1 NPM1 IDH1
NPM1-2 NPM1 DNMT3A, TET2x2
ITD(2x)/NPM1-2 FLT3-ITDx2 NPM1 CEBPA, IDH2
ITD(2x)/NPM1-1 FLT3-ITDx2 NPM1 DNMT3A, IDH2
CEBPA(x2)-3 CEBPAx2, GATA2, TET2
CEBPA(x2)-2 CEBPAx2, GATA2
CEBPA(x2)-1 CEBPAx2
t(8;21)-1 t(8;21) TET2
t(8;21)-1R KIT t(8;21) TET2
t(8;21)-3 FLT3-TK t(8;21)
t(8;21)/KIT-2 KIT t(8;21) NOTCH1
t(8;21)-4 t(8;21)
inv(16)-3 inv(16) ASXL1
inv(16)-2 inv(16)
inv(16)-1 KIT inv(16)
RUNX1-T-7 (NHL) tri(21) RUNX1 TET2x2, PHF6
NPM1/RAS-3 NRAS NPM1 PTPN11, DNMT3A, IDH1
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